20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
C4 Therapeutics Inc (CCCC) operates in the BIOTECHNOLOGY industry and is headquartered in Watertown, United States with about 104 employees. Its market capitalization is roughly $415 million. In the fiscal year ended 2025-12-31, CCCC reported $36M in revenue and ($105M) in net income.
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins.
Interactive charts & full statements → Open the CCCC valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $35M | $36M | $36M | $21M | $31M | $46M | $33M | $21M | $19M |
| Gross Profit | $33M | $28M | $36M | $13M | $31M | $46M | ($45M) | $21M | ($9M) |
| Gross Margin % | 94.9% | 77.8% | 100.0% | 62.7% | 100.0% | 100.0% | -136.3% | 100.0% | -47.7% |
| Operating Income (EBIT) | ($112M) | ($104M) | ($120M) | ($139M) | ($130M) | ($82M) | ($60M) | ($35M) | ($16M) |
| Operating Margin % | -319.0% | -290.7% | -336.1% | -669.8% | -416.6% | -179.4% | -182.1% | -165.8% | -84.6% |
| Net Income | ($101M) | ($105M) | ($105M) | ($132M) | ($128M) | ($84M) | ($66M) | ($34M) | ($16M) |
| Net Margin % | -289.4% | -292.1% | -296.0% | -638.3% | -412.2% | -183.2% | -199.8% | -159.5% | -81.1% |
| EBITDA | ($98M) | ($103M) | ($103M) | ($122M) | ($124M) | ($80M) | ($59M) | ($32M) | ($15M) |
| Earnings Per Share (EPS) | $-1.00 | $-1.27 | $-1.52 | $-2.67 | $-2.62 | $-1.82 | $-1.54 | $-0.79 | $-0.37 |
| Shares Outstanding (M) | 131M | 83M | 69M | 50M | 49M | 46M | 43M | 43M | 42M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $7M | $6M | $11M | $11M | $6M | $7M | $5M | $15M |
| Gross Profit | $7M | $4M | $11M | $11M | $6M | $7M | $3M | $13M |
| Gross Margin % | 100.0% | 70.7% | 100.0% | 100.0% | 100.0% | 100.0% | 65.9% | 86.6% |
| Operating Income (EBIT) | ($26M) | ($28M) | ($23M) | ($34M) | ($29M) | ($29M) | ($38M) | ($28M) |
| Operating Margin % | -397.9% | -451.6% | -210.1% | -306.4% | -441.0% | -402.9% | -728.4% | -183.9% |
| Net Income | ($24M) | ($25M) | ($20M) | ($32M) | ($26M) | ($26M) | ($35M) | ($25M) |
| Net Margin % | -355.9% | -408.5% | -186.0% | -286.4% | -402.6% | -363.7% | -667.8% | -160.6% |
| EBITDA | ($23M) | ($23M) | ($20M) | ($32M) | ($25M) | ($26M) | ($33M) | ($23M) |
| Earnings Per Share (EPS) | $-0.18 | $-0.20 | $-0.18 | $-0.44 | $-0.37 | $-0.37 | $-0.49 | $-0.35 |
| Shares Outstanding (M) | 131M | 126M | 117M | 73M | 71M | 71M | 71M | 70M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($85M) | ($99M) | ($65M) | ($107M) | ($106M) | ($87M) | ($67M) | $56M | ($17M) |
| Capital Expenditures (CapEx) | $1M | $1M | $0M | $2M | $5M | $1M | $1M | $1M | $3M |
| Free Cash Flow (FCF) | ($85M) | ($99M) | ($65M) | ($109M) | ($111M) | ($88M) | ($68M) | $54M | ($20M) |
| FCF Margin % | -243.7% | -276.2% | -183.6% | -523.0% | -358.4% | -192.7% | -204.6% | 253.8% | -101.6% |
| Dividends Paid | — | — | — | — | — | — | $12M | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($2M) | ($30M) | ($22M) | ($31M) | ($12M) | ($33M) | ($18M) | ($24M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($2M) | ($30M) | ($22M) | ($32M) | ($12M) | ($33M) | ($18M) | ($24M) |
| FCF Margin % | -24.3% | -487.8% | -201.1% | -281.6% | -189.4% | -459.9% | -346.5% | -157.2% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $359M | $359M | $350M | $376M | $431M | $507M | $400M | $118M | $146M |
| Cash & Cash Equivalents | $79M | $75M | $55M | $127M | $30M | $76M | $182M | $91M | $36M |
| Total Liabilities | $112M | $102M | $134M | $130M | $142M | $117M | $119M | $230M | $226M |
| Total Debt (Short + Long-Term) | $7M | $6M | $6M | $5M | $16M | $12M | $11M | $1M | $1M |
| Total Shareholders' Equity | $247M | $257M | $216M | $246M | $289M | $390M | $281M | ($112M) | ($80M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CCCC viewer.
About TickerBase · Data methodology & sources · Privacy · Terms